journal article·2022-09-30Open access

Highly tailorable gellan gum nanoparticles as a platform for the development of T cell activator systems

Daniel B. Rodrigues, Helena R. Moreira, Mariana T. Cerqueira, Alexandra P. Marques, António G. Castro, Rui L. Reis, Rogério P. Pirraco

Biomaterials Research· Volume 26· Issue 1

Abstract

Abstract Background T cell priming has been shown to be a powerful immunotherapeutic approach for cancer treatment in terms of efficacy and relatively weak side effects. Systems that optimize the stimulation of T cells to improve therapeutic efficacy are therefore in constant demand. A way to achieve this is through artificial antigen presenting cells that are complexes between vehicles and key molecules that target relevant T cell subpopulations, eliciting antigen-specific T cell priming. In such T cell activator systems, the vehicles chosen to deliver and present the key molecules to the targeted cell populations are of extreme importance. In this work, a new platform for the creation of T cell activator systems based on highly tailorable nanoparticles made from the natural polymer gellan gum (GG) was developed and validated. Methods GG nanoparticles were produced by a water in oil emulsion procedure, and characterized by dynamic light scattering, high resolution scanning electronic microscopy and water uptake. Their biocompatibility with cultured cells was assessed by a metabolic activity assay. Surface functionalization was performed with anti-CD3/CD28 antibodies via EDC/NHS or NeutrAvidin/Biotin linkage. Functionalized particles were tested for their capacity to stimulate CD4 + T cells and trigger T cell cytotoxic responses. Results Nanoparticles were approximately 150 nm in size, with a stable structure and no detectable cytotoxicity. Water uptake originated a weight gain of up to 3200%. The functional antibodies did efficiently bind to the nanoparticles, as confirmed by SDS-PAGE, which then targeted the desired CD4 + populations, as confirmed by confocal microscopy. The developed system presented a more sustained T cell activation over time when compared to commercial alternatives. Concurrently, the expression of higher levels of key cytotoxic pathway molecules granzyme B/perforin was induced, suggesting a greater cytotoxic potential for future application in adoptive cancer therapy. Conclusions Our results show that GG nanoparticles were successfully used as a highly tailorable T cell activator system platform capable of T cell expansion and re-education.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Monoclonal and Polyclonal Antibodies Research · CAR-T cell therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

3B’s Research Group, I3Bs – Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, Barco, 4805-017, Guimarães, Portugal.

ICVS/3B’s – PT Government Associate Laboratory, 4805-017, Braga/Guimarães, Portugal.

School of Medicine, Life and Health Sciences Research Institute (ICVS), University of Minho, Braga, Portugal.

Funding

European Research Council · Fundação para a Ciência e a Tecnologia/ Ministério da Ciência, Tecnologia, e Ensino Superior · Fundo Social Europeu através do Programa Operacional do Capital Humano

References (75)

Show source-provided references
1. 10.1096/fasebj.6.15.146437110.1096/fasebj.6.15.1464371 ↗
2. 10.1038/ni.201810.1038/ni.2018 ↗
3. 10.1016/j.immuni.2011.07.01010.1016/j.immuni.2011.07.010 ↗
4. 10.1038/nri265710.1038/nri2657 ↗
5. 10.1146/annurev.immunol.24.021605.09072710.1146/annurev.immunol.24.021605.090727 ↗
6. 10.1146/annurev.immunol.26.021607.09035710.1146/annurev.immunol.26.021607.090357 ↗
7. 10.1146/annurev.immunol.26.021607.09031610.1146/annurev.immunol.26.021607.090316 ↗
8. 10.1615/CritRevImmunol.201400998810.1615/CritRevImmunol.2014009988 ↗
9. 10.1034/j.1600-065X.2003.00051.x10.1034/j.1600-065X.2003.00051.x ↗
10. 10.1016/S1521-6616(02)00017-710.1016/S1521-6616(02)00017-7 ↗
11. 10.1038/mt.2008.1110.1038/mt.2008.11 ↗
12. 10.1002/eji.20093952210.1002/eji.200939522 ↗
13. Clemente-Casares X Blanco J Ambalavanan P Yamanouchi J Singha S Fandos C et al. Expanding antigen-specific regulatory networks to treat autoimmunity. Nature. 2016;530:434–40. https://doi.org/10.1038/nature16962.10.1038/nature16962 ↗
14. 10.1158/0008-5472.CAN-09-040010.1158/0008-5472.CAN-09-0400 ↗
15. Albani S. Artificial antigen presenting cells. Google Patents; 2004. Available from: https://www.google.com/patents/US6787154
16. 10.1038/nm86910.1038/nm869 ↗
17. 10.1038/mt.sj.630013410.1038/mt.sj.6300134 ↗
18. 10.1038/icb.2016.2510.1038/icb.2016.25 ↗
19. 10.1038/s41392-019-0070-910.1038/s41392-019-0070-9 ↗
20. Arias LS Pessan JP Vieira AP Lima TM Delbem AC Monteiro DR. Iron oxide nanoparticles for biomedical applications: a perspective on synthesis drugs antimicrobial activity and toxicity. Antibiotics. 2018;7(2):46. https://doi.org/10.3390/antibiotics7020046.10.3390/antibiotics7020046 ↗
21. 10.1038/nmat234410.1038/nmat2344 ↗
22. 10.1128/aem.43.5.1086-1091.198210.1128/aem.43.5.1086-1091.1982 ↗
23. 10.1016/0008-6215(83)88361-X10.1016/0008-6215(83)88361-X ↗
24. 10.1016/0966-7822(95)00004-510.1016/0966-7822(95)00004-5 ↗
25. 10.1016/S0144-8617(99)00108-310.1016/S0144-8617(99)00108-3 ↗
26. 10.1016/j.carbpol.2009.11.00510.1016/j.carbpol.2009.11.005 ↗
27. 10.1208/s12249-010-9384-110.1208/s12249-010-9384-1 ↗
28. 10.1016/j.carbpol.2012.05.07110.1016/j.carbpol.2012.05.071 ↗
29. 10.1016/S0378-5173(99)00320-810.1016/S0378-5173(99)00320-8 ↗
30. Shiyani BG, Dholakiyal RB, Akbari BV, Lodhiyal DJ, Ramani GK. Development and evaluation of novel immediate release tablets of Metoclopramide HCI by direct compression using treated gellan gum as disintegration-accelerating agent. J Pharm Res Citeseer. 2009;2:1460–1464. 1:CAS:528:DC%2BC3cXht1WjsbjN
31. 10.1016/j.ejpb.2005.12.00810.1016/j.ejpb.2005.12.008 ↗
32. 10.1016/j.ijpharm.2006.11.00810.1016/j.ijpharm.2006.11.008 ↗
33. Kesavan K, Nath G, Pandit JK. Preparation and in vitro antibacterial evaluation of gatifloxacin mucoadhesive gellan system. Daru. 2010;18:237–46. 1:CAS:528:DC%2BC3MXlslKms7s%3D. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304351/.
34. 10.1208/s12249-010-9413-010.1208/s12249-010-9413-0 ↗
35. 10.1211/jpp.61.06.000510.1211/jpp.61.06.0005 ↗
36. 10.1016/j.actbio.2014.07.00910.1016/j.actbio.2014.07.009 ↗
37. 10.1021/am504520j10.1021/am504520j ↗
38. 10.1016/j.actbio.2014.07.00910.1016/j.actbio.2014.07.009 ↗
39. 10.1016/j.jid.2017.02.97610.1016/j.jid.2017.02.976 ↗
40. 10.1089/ten.tea.2009.011710.1089/ten.tea.2009.0117 ↗
41. Prakash SJ, Santhiagu A, Jasemine S. Preparation, characterization and in vitro evaluation of novel gellan gum-raloxifene HCl nanoparticles. J Pharm Biosc. 2014;2:63–71. http://www.jpbs-online.com/old/abstractba37.html?article_id=1733&title=Preparation.
42. 10.1038/nprot.2007.29610.1038/nprot.2007.296 ↗
43. 10.1038/nmat507210.1038/nmat5072 ↗
44. 10.1186/s40824-018-0133-y10.1186/s40824-018-0133-y ↗
45. 10.1007/s13770-021-00403-710.1007/s13770-021-00403-7 ↗
46. 10.1016/j.jconrel.2006.01.00610.1016/j.jconrel.2006.01.006 ↗
47. 10.1016/j.biomaterials.2010.06.03510.1016/j.biomaterials.2010.06.035 ↗
48. 10.1073/pnas.090274510610.1073/pnas.0902745106 ↗
49. 10.1182/blood-2005-08-337310.1182/blood-2005-08-3373 ↗
50. 10.1007/s12026-009-8156-z10.1007/s12026-009-8156-z ↗
51. 10.1016/j.biomaterials.2016.11.03810.1016/j.biomaterials.2016.11.038 ↗
52. 10.1021/acsnano.5b0282910.1021/acsnano.5b02829 ↗
53. 10.1016/j.nano.2013.06.01510.1016/j.nano.2013.06.015 ↗
54. 10.1016/S1074-7613(01)00096-610.1016/S1074-7613(01)00096-6 ↗
55. Shaji A Zachariah AK. Chapter 9 - Surface area analysis of nanomaterials. In: Thomas S Thomas R Zachariah AK Mishra RKBT-T and RMT for NC editors. Micro Nano Technol. Elsevier; 2017. p. 197–231. Available from: https://www.sciencedirect.com/science/article/pii/B978032346139900009810.1016/B978-0-323-46139-9.00009-8 ↗
56. 10.1186/s40824-018-0123-010.1186/s40824-018-0123-0 ↗
57. 10.1021/acsnano.7b0495510.1021/acsnano.7b04955 ↗
58. 10.1039/C7NR03592F10.1039/C7NR03592F ↗
59. 10.1111/j.1600-065X.2011.01018.x10.1111/j.1600-065X.2011.01018.x ↗
60. 10.1126/science.642985310.1126/science.6429853 ↗
61. 10.1016/j.immuni.2012.02.01710.1016/j.immuni.2012.02.017 ↗
62. 10.1016/j.immuni.2009.11.01210.1016/j.immuni.2009.11.012 ↗
63. 10.1038/nm.219810.1038/nm.2198 ↗
64. Thompson JA, Lee DJ, Cox WW, Lindgren CG, Collins C, Neraas KA, et al. Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. Cancer Res AACR. 1987;47:4202–4207. 1:STN:280:DyaL2s3ntlajtA%3D%3D
65. 10.1016/j.cyto.2014.11.02410.1016/j.cyto.2014.11.024 ↗
66. 10.1038/ni.203510.1038/ni.2035 ↗
67. 10.4049/jimmunol.080421110.4049/jimmunol.0804211 ↗
68. 10.1038/nri108310.1038/nri1083 ↗
69. 10.1038/ncomms943710.1038/ncomms9437 ↗
70. 10.1074/jbc.273.43.2793410.1074/jbc.273.43.27934 ↗
71. 10.1002/eji.183023041910.1002/eji.1830230419 ↗
72. 10.1016/j.cyto.2012.02.00710.1016/j.cyto.2012.02.007 ↗
73. 10.1128/cdli.3.3.301-304.199610.1128/cdli.3.3.301-304.1996 ↗
74. 10.1046/j.1365-3083.1998.00366.x10.1046/j.1365-3083.1998.00366.x ↗
75. 10.4049/jimmunol.166.6.390010.4049/jimmunol.166.6.3900 ↗